STAND. COM. REP. NO. 3958

Honolulu, Hawaii

RE: H.B. No. 2260

H.D. 1

S.D. 2

Honorable Ronald D. Kouchi

President of the Senate

Thirty-First State Legislature

Regular Session of 2022

State of Hawaii

Sir:

Your Committees on Judiciary and Ways and Means, to which was referred H.B. No. 2260, H.D. 1, S.D. 1, entitled:

"A BILL FOR AN ACT RELATING TO CANNABIS,"

beg leave to report as follows:

The purpose and intent of this measure is to:

(1) Amend the circumstances under which medical cannabis may be transported by and between dispensaries;

(2) Increase the allowable number of plants for production centers;

(3) Increase the number of production centers that may be allowed under a dispensary license;

(4) Increase the number of retail dispensing locations that may be allowed under a dispensary license;

(5) Redefine the term "medical cannabis production center" to include any series of structures located within the same secured perimeter fence-line;

(6) Require the Department of Health to establish the fee structure for the submission of applications for additional production centers and retail dispensing locations and for dispensary-to-dispensary sales; and

(7) Amend the Department of Health's duties with respect to the establishment of standards for manufactured cannabis products.

Your Committees received testimony in support of this measure from Aloha Green Holdings Inc., Maui Grown Therapies, Hawai‘i Cannabis Industry Association, Hawaiian Ethos, Green Aloha, Big Island Grown, and over eight hundred individuals. Your Committees received testimony in opposition to this measure from Patients Without Time and six individuals. Your Committees received comments on this measure from the Department of Health, Akamai Cannabis Consulting, Hawaii Cannabis Hui, and one individual.

Your Committees have amended this measure by:

(1) Deleting language that would have required the Department of Health to establish the fee structure for the submission of applications for additional production centers and retail dispensing locations and for dispensary-to-dispensary sales;

(2) Deleting language that would have required the Department of Health to establish manufacturing and product stability standards regarding the manufacture of manufactured cannabis products; and

(3) Making technical, nonsubstantive amendments for the purposes of clarity and consistency.

As affirmed by the records of votes of the members of your Committees on Judiciary and Ways and Means that are attached to this report, your Committees are in accord with the intent and purpose of H.B. No. 2260, H.D. 1, S.D. 1, as amended herein, and recommend that it pass Third Reading in the form attached hereto as H.B. No. 2260, H.D. 1, S.D. 2.

Respectfully submitted on behalf of the members of the Committees on Judiciary and Ways and Means,

________________________________ DONOVAN M. DELA CRUZ, Chair

________________________________ KARL RHOADS, Chair